Companies
Wyss Center
the non-profit Wyss Center develops the fully-implanted Wyss Able ECoG system for home (not only lab) use in locked-in syndrome, and a 5-year follow-up of a fully implanted BCI in a spinal-cord-injury patient was published in 2025; its academic partners have demonstrated a streaming brain-to-voice neuroprosthesis.
- Country
- Switzerland
- Ticker
- non-profit
ECoG research platform
Non-profit research
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $50 million total investment over 8+ years at the Wyss Center prior to spinout | abilityneuro.com · insidebci.com · massdevice.com |
| Certification | ISO 13485:2016 for its Quality Management System | wysscenter.ch |
| Regulatory approval | Investigational Medical Device Dossier approval for a chronic clinical trial in the Netherlands | wysscenter.ch |
| Headcount | 60 employees at the Wyss Center (as of 2022) | businesswire.com |
| Headquarters | Geneva, Switzerland | businesswire.com · wyssfoundation.org · wysscenter.ch |
Independent sources: abilityneuro.com · businesswire.com · insidebci.com · massdevice.com · wyssfoundation.org
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Neurointerfaces & brain–computer interfaces | regenerative-personalized | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.